by Pulmonary edema refers to the accumulation of fluid in the alveoli or air spaces of the lungs. It can be caused by various factors such as left ventricular failure, cardiogenic pulmonary edema, high altitude sickness, fluid overload, chest injury, etc. Pulmonary edema therapeutics include medications such as diuretics, vasodilators, ACE inhibitors, calcium channel blockers and supplemental oxygen which help reduce symptoms and resolve fluid build-up in the lungs. The growing incidence of cardiovascular diseases such as congestive heart failure, myocardial infarction and hypertension resulting in pulmonary edema is a major driver for the pulmonary edema therapeutics market.
The global Pulmonary Edema Therapeutics Market is estimated to be valued at US$ 12144.1 Mn in 2023 and is expected to exhibit a CAGR of 5.4% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
Increasing prevalence of cardiovascular diseases is a key trend driving growth of the pulmonary edema therapeutics market. Cardiovascular diseases such as congestive heart failure, myocardial infarction and hypertension can lead to pulmonary edema. According to World Health Organization (WHO), cardiovascular diseases are the number one cause of death globally, taking an estimated 17.9 million lives each year. The increasing geriatric population also contributes significantly to the rising incidence of cardiovascular diseases and pulmonary edema, as the risk of developing such conditions grows with age. This rising prevalence of underlying cardiovascular conditions is expected to propel demand for pulmonary edema therapeutics over the forecast period.
SWOT Analysis
Strength: The global pulmonary edema therapeutics market continues to witness strong research and development activities which is expected to result in new and improved treatment options.
Weakness: High costs associated with treatment and lack of awareness about pulmonary edema in some regions are some of the weaknesses of this market.
Opportunity: Rising incidence of pulmonary edema cases due to increasing risk factors such as surge in smoking rates, chronic kidney disease cases is expected to generate several growth opportunities.
Threats: Strong competition from alternative treatment options and expiry of patents of blockbuster drugs are some of the threats faced by players in this market.
Key Takeaways
The Global Pulmonary Edema Therapeutics Market is expected to witness high growth over the forecast period of 2023 to 2030. The global Pulmonary Edema Therapeutics Market is estimated to be valued at US$ 12144.1 Mn in 2023 and is expected to exhibit a CAGR of 5.4% over the forecast period 2023 to 2030.
North America is expected dominate the global pulmonary edema therapeutics market over the forecast period. This is attributed to the presence of major players who are engaged in developing new and improved treatment options. Europe is also expected to grow at a steady pace due to high awareness about disease diagnosis and management.
Key players
Key players operating in the pulmonary edema therapeutics market are Crayola LLC, Faber-Castell AG, Sargent Art, Reeves (Colart Group), Liquitex (Colart Group), Sax Arts & Crafts, Prang (Dixon Ticonderoga Company), RASCHER GmbH, Richeson Art Materials, Jovi S.L. These players are focused on developing new drug formulations and combination therapies to strengthen their market position. For instance, Crayola LLC launched a new line of edema tablets with improved bioavailability in 2021.
